What it is
Pasireotide is a ring of six amino acids built to act like somatostatin, the body's own "switch-off" hormone for growth hormone, insulin and several other secretions. The Signifor label calls it "an injectable cyclohexapeptide somatostatin analogue". Natural somatostatin is a 14-amino-acid hormone, covered in the library's somatostatin entry. Pasireotide is one of three shorter, longer-lasting analogues in clinical use, alongside octreotide and lanreotide.
| Property | Value | Source |
|---|---|---|
| Structure | Cyclohexapeptide (six-residue ring) | Signifor label sections 11, 12.1 |
| Formula | C58H66N10O9 | PubChem CID 9941444 |
| Molecular weight | 1,047.2 | PubChem |
| Salt forms | Diaspartate (Signifor); pamoate (Signifor LAR) | Labels, section 11 |
| Routes | Subcutaneous twice daily; intramuscular every 4 weeks | Labels, section 2 |
How it acts. Somatostatin works through five receptor subtypes, SSTR1 to SSTR5. In the label's laboratory binding table pasireotide's strongest affinity is at SSTR5 (IC50 0.16 nmol/L, against 0.29 for natural somatostatin), followed by SSTR2 (1.0), SSTR3 (1.5) and SSTR1 (9.3), with almost none at SSTR4 (above 100). The Signifor label states that corticotroph tumour cells — the pituitary cells that over-produce ACTH in Cushing's disease — "frequently over-express SSTR5", and that pasireotide "binds and activates the SSTRs resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion". Lower ACTH means less cortisol from the adrenal glands (the library's ACTH entry explains the chain). In acromegaly, the target is growth hormone and the IGF-1 it drives.
What the trials showed
Cushing's disease (Signifor, twice daily). A phase III multicentre trial randomised 162 patients — 78% women, mean age 40, 83% with disease that persisted or returned after pituitary surgery — to 0.6 mg or 0.9 mg twice daily for six months, then six months open-label. Median baseline urinary free cortisol was 565 nmol/24 h against a normal range of 30–145.
| End point at month 6 | 0.6 mg twice daily | 0.9 mg twice daily |
|---|---|---|
| Normal 24-h urinary free cortisol, no dose increase (primary) | 15% | 26% |
| Normal or ≥50% reduction | 34% | 41% |
The label adds that "dose increases appeared to have minimal effect" on urinary cortisol, and about two-thirds of patients completed six months. There was no placebo arm: the trial compared two doses.
Acromegaly (Signifor LAR, monthly). In 358 drug-naïve patients randomised 1:1 to Signifor LAR 40 mg or another somatostatin analogue (the label does not name it), 31.3% v 19.2% reached mean growth hormone below 2.5 mcg/L with a normal age- and sex-adjusted IGF-1 at month 12. The label notes that the comparator's maximum US dose was not used, because the trial ran in countries where that dose was not approved — a limit on how far the comparison can be read.
What is not established: a placebo-controlled effect size in Cushing's disease, and any use outside the labelled pituitary conditions.
Risks the labels list
- Most common (20% or more, Signifor): diarrhoea, nausea, hyperglycaemia, gallstones, headache, abdominal pain, fatigue and diabetes mellitus. Signifor LAR's list is similar (diarrhoea, gallstones, hyperglycaemia).
- Blood sugar: both labels require fasting plasma glucose and HbA1c before treatment; Signifor LAR's warnings name ketoacidosis as well as hyperglycaemia and diabetes.
- Before the first dose (Signifor): liver tests, ECG, gallbladder ultrasound, potassium and magnesium.
- Other warnings: low cortisol, slow heart rate and QT prolongation, liver-test elevations, deficiency of other pituitary hormones, and malabsorption of dietary fat.
- Liver impairment: Signifor starts at 0.3 mg twice daily, maximum 0.6 mg, in moderate (Child-Pugh B) impairment.
Where it stands
Both forms are US prescription drugs held by Recordati Rare Diseases: Signifor, NDA 200677, original approval 14 December 2012, and Signifor LAR, NDA 203255, original approval 15 December 2014 (Drugs@FDA, read 2026-11-20). The current Signifor label is effective 17 February 2026 and the Signifor LAR label 16 July 2024.
Sources opened 2026-11-20: Signifor label (openFDA, effective 2026-02-17: sections 1, 2, 6, 11, 12.1, 14); Signifor LAR label (openFDA, effective 2024-07-16: sections 1, 2, 6, 11, 12.1, 14.1); Drugs@FDA records for NDA 200677 and NDA 203255; PubChem CID 9941444; PubMed E-utilities and ClinicalTrials.gov API v2 counts.
